- Home
- WAT vs ILMN Comparison
WAT vs ILMN Comparison
Compare WAT & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WAT
- ILMN
- Stock Information
- Founded
- WAT 1958
- ILMN 1998
- Country
- WAT United States
- ILMN United States
- Employees
- WAT N/A
- ILMN N/A
- Industry
- WAT Biotechnology: Laboratory Analytical Instruments
- ILMN Medical Specialities
- Sector
- WAT Industrials
- ILMN Health Care
- Exchange
- WAT Nasdaq
- ILMN Nasdaq
- Market Cap
- WAT 22.5B
- ILMN 23.1B
- IPO Year
- WAT 1995
- ILMN 2000
- Fundamental
- Price
- WAT $358.52
- ILMN $135.05
- Analyst Decision
- WAT Hold
- ILMN Buy
- Analyst Count
- WAT 14
- ILMN 20
- Target Price
- WAT $357.85
- ILMN $160.68
- AVG Volume (30 Days)
- WAT 527.7K
- ILMN 2.0M
- Earning Date
- WAT 11-01-2024
- ILMN 11-04-2024
- Dividend Yield
- WAT N/A
- ILMN N/A
- EPS Growth
- WAT N/A
- ILMN N/A
- EPS
- WAT 10.48
- ILMN N/A
- Revenue
- WAT $2,905,147,000.00
- ILMN $4,390,000,000.00
- Revenue This Year
- WAT $0.49
- ILMN N/A
- Revenue Next Year
- WAT $5.55
- ILMN $4.00
- P/E Ratio
- WAT $34.22
- ILMN N/A
- Revenue Growth
- WAT N/A
- ILMN N/A
- 52 Week Low
- WAT $258.90
- ILMN $90.17
- 52 Week High
- WAT $393.38
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- WAT 47.62
- ILMN 37.03
- Support Level
- WAT $378.48
- ILMN $149.05
- Resistance Level
- WAT $388.00
- ILMN $156.66
- Average True Range (ATR)
- WAT 9.84
- ILMN 5.17
- MACD
- WAT 0.31
- ILMN -1.85
- Stochastic Oscillator
- WAT 51.62
- ILMN 7.01
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.